Novolytics was formed specifically to help overcome the problems of antibacterial resistance.

Novolytics products exploit the use of bacteriophages – environmentally natural killers of pathogenic bacteria,
which are 100% specific to the target pathogen. The first
of Novolytics’ products is a treatment for infection with the hospital ‘superbug’, Methicillin Resistant Staphylococcus
aureus (MRSA).